Literature DB >> 8686457

Bisphosphonate inhibition of bone resorption induced by particulate biomaterial-associated macrophages.

R Pandey1, J M Quinn, A Sabokbar, N A Athanasou.   

Abstract

Aseptic loosening of total joint replacements is associated with bone resorption. A heavy infiltrate of foreign body macrophages in response to biomaterial wear particles is commonly found in the fibrous membrane surrounding loose components. It has recently been shown that foreign body macrophages can differentiate into osteoclastic cells. To determine whether pharmacological inhibitors of bone resorption have a role to play in controlling the osteolysis of aseptic loosening, we analyzed the effect of a bisphosphonate, disodium ethane-1, 1-diphosphonate (EHDP) on this process. Murine monocytes and foreign body macrophages (derived from granulomas formed by subcutaneous implantation of particles of prosthetic biomaterials) were co-cultured with UMR106 osteoblast-like cells in the presence of 1,25 dihydroxyvitamin D3 for 14 days on glass coverslips and bone slices. EHDP significantly inhibited bone resorption in these co-cultures. There was little or no expression of the osteoclast-associated enzyme, tartrate-resistant acid phosphatase (TRAP) in EHDP-treated co-cultures. Addition of EHDP to monocyte-UMR106 co-cultures after the appearance of TRAP-positive cells did not abolish bone resorption, indicating that EHDP, in addition to its known inhibitory effect on osteoclast function, suppresses differentiation of osteoclast precursors. EHDP inhibition of the osteolysis induced by particulate biomaterial-associated macrophages shows that pharmacological inhibition of bone resorption might be used to control the osteolysis of aseptic loosening.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8686457     DOI: 10.3109/17453679608994677

Source DB:  PubMed          Journal:  Acta Orthop Scand        ISSN: 0001-6470


  8 in total

1.  Periprosthetic bone density as outcome of therapeutic response.

Authors:  Giovanni Iolascon; Gioconda Di Pietro; Annarita Capaldo; Carmine Gioia; Salvatore Gatto; Francesca Gimigliano
Journal:  Clin Cases Miner Bone Metab       Date:  2010-01

2.  Bisphosphonates in bone cement inhibit PMMA particle induced bone resorption.

Authors:  A Sabokbar; Y Fujikawa; D W Murray; N A Athanasou
Journal:  Ann Rheum Dis       Date:  1998-10       Impact factor: 19.103

3.  Fibroblasts from the inner granulation tissue of the pseudocapsule in hips at revision arthroplasty induce osteoclast differentiation, as do stromal cells.

Authors:  H Sakai; S Jingushi; T Shuto; K Urabe; T Ikenoue; K Okazaki; T Kukita; A Kukita; Y Iwamoto
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

4.  Bisphosphonate treatment for osteolysis in total hip arthroplasty. A report of four cases.

Authors:  Carlo Trevisan; Veronica Nava; Marta Mattavelli; Cleber Garcia Parra
Journal:  Clin Cases Miner Bone Metab       Date:  2013-01

5.  Apoptosis in interface membranes of aseptically loose total hip arthroplasty.

Authors:  O L Huk; D J Zukor; W Ralston; A Lisbona; A Petit
Journal:  J Mater Sci Mater Med       Date:  2001-07       Impact factor: 3.896

6.  Enhancing alendronate release from a novel PLGA/hydroxyapatite microspheric system for bone repairing applications.

Authors:  Xuetao Shi; Yingjun Wang; Li Ren; Yihong Gong; Dong-An Wang
Journal:  Pharm Res       Date:  2008-11-01       Impact factor: 4.200

7.  Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone.

Authors:  Maurice Balke; Laura Campanacci; Carsten Gebert; Piero Picci; Max Gibbons; Richard Taylor; Pancras Hogendoorn; Judith Kroep; John Wass; Nicholas Athanasou
Journal:  BMC Cancer       Date:  2010-08-29       Impact factor: 4.430

8.  Biocompatibility issues with modern implants in bone - a review for clinical orthopedics.

Authors:  Katja M R Nuss; Brigitte von Rechenberg
Journal:  Open Orthop J       Date:  2008-04-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.